SNC-Lavalin Awarded Contracts by Merck Frosst Canada &
Co.
MONTREAL, QUEBEC--JULY 6, 2000--SNC-Lavalin Pellemon, a wholly-owned subsidiary
of SNC-Lavalin, has announced that it has been awarded engineering
contracts for a series of projects at the Kirkland, Quebec complex
of Merck Frosst Canada & Co. Capital costs for these projects
total more than $100 million.
The projects include the renovation and expansion of the current
research and development facilities at the Merck Frosst Centre for
Therapeutic Research, one of Canada's largest biomedical research
facilities, in addition to the construction of a new corporate
head office.
SNC-Lavalin Pellemon will provide engineering and architectural
services for the projects, which will be completed within the
scope of a long-standing 12-year partnership between SNC-Lavalin
Pellemon and Merck Frosst Canada & Co., both in Canada and abroad.
SNC-Lavalin Group is one of the leading engineering and
construction firms in the world, and a key player in the ownership
and management of infrastructure. The group and its companies
have offices across Canada and in 30 other countries, and are
currently working in some 100 countries. The company is listed on
the Toronto Stock Exchange (symbol: SNC). |
